- To expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies
- Salzman Group will share its expertise in working with nitric oxide and nitric oxide-releasing compounds
- R-107 can be administered orally, by injection or by use of a nasal spray
- R-107 is expected to allow treatment without the need for special delivery equipment or trained respiratory therapists
- Phase 1 clinical study of intramuscular R-107 will be conducted at CMAX in Adelaide
- Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
- Claritas (KLY) is down 15.38 per cent, trading at C$0.55 per share at 1 pm EST
Claritas Pharmaceuticals has entered into a strategic collaboration agreement with Salzman Group, to expedite the development of R-107.
Claritas is in the process of entering into similar collaborative agreements with other companies.
To expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies for the manufacture of R-107, and for the design and completion of clinical studies to demonstrate the safety and efficacy of R-107 in the treatment of COVID-19, influenza, and other viral infections.
Under the agreement, Salzman Group will make available to Claritas its expertise in working with nitric oxide and nitric oxide-releasing compounds.
Salzman Group will also provide a platform of services, including expertise in the manufacture of R-107, design of clinical studies, and consulting services in connection with Claritas’ interactions with regulatory bodies in the USA, Australia, the UK, and the EU.
“Nitric oxide has a well-documented safety profile and has been demonstrated to be effective against a wide variety of viruses,” stated Dr. Andrew Salzman, Chairman of the Salzman Group.
“Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas, and must be administered by inhalation therapy. Our group has worked to design a nitric oxide-releasing compound to overcome these issues.
This multi-year effort was successful, and resulted in the invention of R-107, which can be administered orally as a capsule, or nasally through use of a nasal spray, or by injection.”
Dr. Salzman continued,
“We are delighted to be working with Claritas to develop R-107, not only as a therapy for vaccine-resistant COVID-19 infection but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.”
The Phase 1 clinical study of intramuscular R-107 will be conducted at CMAX, a clinical contract research organization located at Royal Adelaide Hospital in Australia.
Claritas is in discussions with CMAX regarding a strategic collaboration, under which CMAX will use best efforts to expedite the completion of the Phase 1 study.
Claritas is also engaged in similar discussions with PCI Pharma Services, an Australian company that will provide formulation and logistical services in connection with the Phase 1 study.
Professor Salvatore Cuzzocrea, President of the University of Messina and former President of the European Shock Society is working with Salzman Group and Claritas, and has read and approved of the scientific disclosure in this news release.
Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
Claritas (KLY) is down 15.38 per cent, trading at C$0.55 per share at 1 pm EST.
